David S. Reasner
Ironwood Pharmaceuticals
27 Papers
24 Citations
David S. Reasner is an academic researcher from Ironwood Pharmaceuticals. The author has contributed to research in topics: Medicine & Irritable bowel syndrome. The author has an hindex of 7, co-authored 22 publications.
Chat about Author
Papers
Response scale selection in adult pain measures: results from a literature review
Shima Safikhani,Katharine S. Gries,Jeremiah J. Trudeau,David S. Reasner,Katja Rüdell,Stephen Joel Coons,Elizabeth Nicole Bush,Jennifer Hanlon,Lucy Abraham,Margaret Vernon +9 more
TL;DR: Both empirical studies and review articles provide evidence that the 11-point NRS is likely the optimal response scale to evaluate pain among adult patients without cognitive impairment.
Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions
Yunsheng Yang,Jingyuan Fang,Xiaozhong Guo,Ning Dai,Xizhong Shen,Youlin Yang,Jing Sun,Bal Raj Bhandari,David S. Reasner,Jacquelyn A. Cronin,Mark G. Currie,Jeffrey M. Johnston,Peter Zeng,Niwat Montreewasuwat,G. Chen,Sam Lim,Sam Lim +16 more
TL;DR: This trial evaluated linaclotide's efficacy and safety in IBS‐C patients in China and other regions for unmet need for well‐tolerated therapy.
74
Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation.
William D. Chey,Gregory S. Sayuk,Wilmin Bartolini,David S. Reasner,Susan M. Fox,Wieslaw Bochenek,Ramesh Boinpally,Elizabeth P. Shea,Kenneth Tripp,Niels Borgstein +9 more
TL;DR: Persistent, modest abdominal pain improvement with limited impact on bowel symptom parameters, as seen across MD-7246 doses, warrants further study of MD- 7246 as a novel treatment for abdominal pain, regardless of IBS subtype.
49
IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial.
Michael F. Vaezi,Ronnie Fass,Nimish Vakil,David S. Reasner,Robert S. Mittleman,Michael Hall,James Z. Shao,Yan Chen,Lara Lane,Amy M. Gates,Mark G. Currie +10 more
TL;DR: In a randomized trial of patients with refractory GERD, adding 1500-mg IW-3718 to label-dose PPIs significantly reduced heartburn symptoms compared with adding placebo, and Regurgitation symptoms also decreased.
38
Development of a Symptom-Focused Patient-Reported Outcome Measure for Functional Dyspepsia: The Functional Dyspepsia Symptom Diary (FDSD)
Fiona Taylor,Sophie Higgins,Robyn T. Carson,Sonya Eremenco,Catherine Foley,Brian E. Lacy,Henry P. Parkman,David S. Reasner,Alan L. Shields,Jan Tack,Nicholas J. Talley +10 more
TL;DR: The Functional Dyspepsia Symptom Diary is a content-valid PRO measure, with preliminary psychometric evidence providing support for the FDSD’s items and total score, and further psychometric evaluations are recommended to more fully test the F DSD‘s score performance and other measurement properties in the target patient population.
21